Literature DB >> 26229391

Gastrointestinal cancers in the era of theranostics: Updates and future perspectives.

Marwan Ghosn1, Hampig Raphael Kourie1, Samer Tabchi1.   

Abstract

Theranostics are one of the practical aspects of personalized medicine. This concept was designed to describe a material combining diagnosis, treatment and follow up of a disease. It evolved and included molecular targeting and nanotechnologies that incorporate both diagnosis and therapeutics. In this editorial, we are presenting briefly the concept and evolution of theranostics, highlighting many applications of theranostics in daily practice and discussing future perspectives and aspects of this model in gastro-intestincal cancers.

Entities:  

Keywords:  Gastrointestinal cancer; Molecular targeting; Nanoparticles; Nanotheranostics; Theranostics

Mesh:

Substances:

Year:  2015        PMID: 26229391      PMCID: PMC4515830          DOI: 10.3748/wjg.v21.i28.8473

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Oophorectomy for breast cancer: history revisited.

Authors:  Richard R Love; John Philips
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

Review 2.  Theranostic nanomedicine for cancer.

Authors:  Baran Sumer; Jinming Gao
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

3.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

4.  Polymeric nanoparticle preparation that eradicates tumors.

Authors:  Jason R McCarthy; J Manuel Perez; Christian Brückner; Ralph Weissleder
Journal:  Nano Lett       Date:  2005-12       Impact factor: 11.189

5.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

Review 6.  Trastuzumab containing regimens for early breast cancer.

Authors:  Lorenzo Moja; Ludovica Tagliabue; Sara Balduzzi; Elena Parmelli; Vanna Pistotti; Valentina Guarneri; Roberto D'Amico
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 7.  Advances in targeted therapy for unresectable melanoma: new drugs and combinations.

Authors:  Mengze Hao; Fengju Song; Xiaoling Du; Guowen Wang; Yun Yang; Kexin Chen; Jilong Yang
Journal:  Cancer Lett       Date:  2015-01-08       Impact factor: 8.679

8.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

Review 9.  Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.

Authors:  Ling Wang; Kun Tang; Qi Zhang; Huanbin Li; Zhengwei Wen; Hongzheng Zhang; Hong Zhang
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

10.  HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.

Authors:  Y J Liu; D Shen; X Yin; P Gavine; T Zhang; X Su; P Zhan; Y Xu; J Lv; J Qian; C Liu; Y Sun; Z Qian; J Zhang; Y Gu; X Ni
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

View more
  2 in total

Review 1.  Recent advances in targeted drug delivery systems for resistant colorectal cancer.

Authors:  Masoumeh Sharifi-Azad; Marziyeh Fathi; William C Cho; Abolfazl Barzegari; Hamed Dadashi; Mehdi Dadashpour; Rana Jahanban-Esfahlan
Journal:  Cancer Cell Int       Date:  2022-05-19       Impact factor: 6.429

2.  Impact of Poly (Styrene-Acrylic Acid) Latex Nanoparticles on Colorectal and Cervical Cancer Cells.

Authors:  Munther Alomari; Arwa Almahasheer; Balasamy Rabindran Jermy; Amal A Al-Dossary; Hiba Bahmdan; Vijaya Ravinayagam; Deena Ababneh; Mohamad Tarhini; Abdelhamid Elaissari
Journal:  Polymers (Basel)       Date:  2021-06-22       Impact factor: 4.329

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.